Bold claim: a single pen now delivers a full month of Zepbound doses, promising greater convenience for people managing obesity. But here’s where it gets controversial: does simplifying the delivery method truly improve adherence and outcomes, or does it introduce new challenges in dosing and access?
Eli Lilly expanded its Zepbound offering with a multi-dose injection pen named KwikPen, designed to provide a month’s supply in one device. This option is available to cash-paying patients through LillyDirect, the company’s direct-to-consumer site, with prices starting at $299 per month for the lowest dose level.
For many patients, the KwikPen could be a simpler alternative that reduces the number of devices used each month. Instead of swapping a new device weekly, patients can administer four weekly doses with a single pen. By comparison, the current regimen typically uses a different single-dose autoinjector each week. Lilly also continues to offer single-dose vials of Zepbound, which require users to draw the medication into a syringe and inject themselves.
The timing of the KwikPen launch aligns with Lilly’s ongoing effort to sustain Zepbound’s rapid market momentum, which has soared since the drug’s late-2023 entry. A key driver has been LillyDirect, the company’s consumer platform, and introducing a more convenient form could attract additional patients and further expand user adoption.
Zepbound’s rapid growth has helped Eli Lilly capture a sizable share of the weight-management drug market, increasing competition with Novo Nordisk. In Lilly’s latest quarterly results, Zepbound generated $4.2 billion in U.S. revenue, marking a 122% year-over-year increase.
Lilly notes that the U.S. Food and Drug Administration approved the label expansion to accommodate the multi-dose KwikPen for Zepbound. The KwikPen is already employed for other Lilly therapies, including Mounjaro, the company’s widely used diabetes medication.
“As part of our commitment to supporting people living with obesity in their weight-management journey, we are introducing a new option with the Zepbound KwikPen, a device trusted by patients globally and in the United States for other Lilly medicines,” stated Ilya Yuffa, president of Lilly USA and Global Customer Capabilities, in the release.
Would you prefer a pay-per-month model with a single pen, or are you comfortable with the existing weekly-delivery approach? And what questions do you have about how a multi-dose device might affect your daily routine, cost, or treatment plan?
